Molecular Testing of Lung Cancers
- Authors
- Shim, Hyo Sup; Choi, Yoon-La; Kim, Lucia; Chang, Sunhee; Kim, Wan-Seop; Roh, Mee Sook; Kim, Tae-Jung; Ha, Seung Yeon; Chung, Jin-Haeng; Jang, Se Jin; Lee, Geon Kook
- Issue Date
- May-2017
- Publisher
- KOREAN SOC PATHOLOGISTS
- Keywords
- Lung neoplasms; Molecular testing; Guideline; Precision medicine
- Citation
- JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, v.51, no.3, pp.242 - 254
- Journal Title
- JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE
- Volume
- 51
- Number
- 3
- Start Page
- 242
- End Page
- 254
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6146
- DOI
- 10.4132/jptm.2017.04.10
- ISSN
- 2383-7837
- Abstract
- Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories-mutations, gene rearrangements, and amplifications-and propose expanded guidelines on molecular testing of lung cancers.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6146)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.